表紙
市場調査レポート

vasopharm GmbH - 製品パイプラン分析

vasopharm GmbH - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 310649
出版日 ページ情報 英文 22 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
vasopharm GmbH - 製品パイプラン分析 vasopharm GmbH - Product Pipeline Review - 2014
出版日: 2014年08月14日 ページ情報: 英文 22 Pages
概要

vasopharm GmbH は、脳および循環器疾患、そしてその後遺症の治療薬の創薬と開発に取り組む製薬会社です。製品には外傷性脳損傷や、末梢動脈閉塞性疾患の治療薬が含まれています。同社はまた外部機関とも幅広く提携しています。

当レポートでは、vasopharm GmbHにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

vasopharm GmbHの基本情報

vasopharm GmbHの概要

  • 主要情報
  • 企業情報

vasopharm GmbH:R&Dの概要

  • 主な治療範囲

vasopharm GmbH:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

vasopharm GmbH:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

vasopharm GmbH:薬剤プロファイル

  • VAS-203
  • VAS-2870
  • VAS-3947

vasopharm GmbH:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

vasopharm GmbH:最近のパイプライン動向

vasopharm GmbH:本社と子会社の所在地

付録

図表

目次
Product Code: GMDHC06149CDB

Summary

Global Markets Direct's, 'vasopharm GmbH - Product Pipeline Review - 2014', provides an overview of the vasopharm GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of vasopharm GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of vasopharm GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of vasopharm GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the vasopharm GmbH's pipeline products

Reasons to buy

  • Evaluate vasopharm GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of vasopharm GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the vasopharm GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of vasopharm GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of vasopharm GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of vasopharm GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • vasopharm GmbH Snapshot
    • vasopharm GmbH Overview
    • Key Information
    • Key Facts
  • vasopharm GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • vasopharm GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • vasopharm GmbH - Pipeline Products Glance
    • vasopharm GmbH - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • vasopharm GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • vasopharm GmbH - Drug Profiles
    • VAS-203
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAS-2870
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAS-3947
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • vasopharm GmbH - Pipeline Analysis
    • vasopharm GmbH - Pipeline Products by Target
    • vasopharm GmbH - Pipeline Products by Route of Administration
    • vasopharm GmbH - Pipeline Products by Molecule Type
    • vasopharm GmbH - Pipeline Products by Mechanism of Action
  • vasopharm GmbH - Recent Pipeline Updates
  • vasopharm GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • vasopharm GmbH, Key Information
  • vasopharm GmbH, Key Facts
  • vasopharm GmbH - Pipeline by Indication, 2014
  • vasopharm GmbH - Pipeline by Stage of Development, 2014
  • vasopharm GmbH - Monotherapy Products in Pipeline, 2014
  • vasopharm GmbH - Phase II, 2014
  • vasopharm GmbH - Preclinical, 2014
  • vasopharm GmbH - Pipeline by Target, 2014
  • vasopharm GmbH - Pipeline by Route of Administration, 2014
  • vasopharm GmbH - Pipeline by Molecule Type, 2014
  • vasopharm GmbH - Pipeline Products by Mechanism of Action, 2014
  • vasopharm GmbH - Recent Pipeline Updates, 2014

List of Figures

  • vasopharm GmbH - Pipeline by Top 10 Indication, 2014
  • vasopharm GmbH - Pipeline by Stage of Development, 2014
  • vasopharm GmbH - Monotherapy Products in Pipeline, 2014
  • vasopharm GmbH - Pipeline by Top 10 Target, 2014
  • vasopharm GmbH - Pipeline by Top 10 Molecule Type, 2014
  • vasopharm GmbH - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top